Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 09, 2020 at 01:25 pm EST
Share
Yung Zip Chemical Ind. Co., Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 111.852 million compared to TWD 99.702 million a year ago. Operating loss was TWD 3.119 million compared to TWD 3.707 million a year ago. Net loss was TWD 3.683 million compared to net income of TWD 5.684 million a year ago. Basic loss per share was TWD 0.09 compared to basic earnings per share of TWD 0.13 a year ago. For the nine months, sales was TWD 336.501 million compared to TWD 313.991 million a year ago. Operating income was TWD 20.244 million compared to TWD 13.645 million a year ago. Net income was TWD 23.250 million compared to TWD 24.708 million a year ago. Basic earnings per share was TWD 0.55 compared to TWD 0.58 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
